Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report

Mehmet Erdem Çakmak
Saltuk Buğra Kaya
Özge Can Bostan
Gülseren Tuncay
Ebru Damadoğlu
Gül Karakaya
Ali Fuat Kalyoncu

Abstract

Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world. SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases. There are concerns that COVID-19 will be more severe in patients with severe asthma. The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown. In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19. To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma.

Keywords

COVID-19, asthma, omalizumab, severe allergic asthma, anti-IgE
Tüm hakları saklıdır. © 2016 AAI